[go: up one dir, main page]

NL940007I1 - Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten de verkregen gevormde farmaceutische preparaten alsmede werkwijzeter bereiding van de toe te passen benz(aryl)azep inederivaten - Google Patents

Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten de verkregen gevormde farmaceutische preparaten alsmede werkwijzeter bereiding van de toe te passen benz(aryl)azep inederivaten

Info

Publication number
NL940007I1
NL940007I1 NL940007C NL940007C NL940007I1 NL 940007 I1 NL940007 I1 NL 940007I1 NL 940007 C NL940007 C NL 940007C NL 940007 C NL940007 C NL 940007C NL 940007 I1 NL940007 I1 NL 940007I1
Authority
NL
Netherlands
Prior art keywords
benz
aryl
pharmaceutical preparations
azepine derivatives
preparing
Prior art date
Application number
NL940007C
Other languages
English (en)
Other versions
NL940007I2 (nl
Original Assignee
Akzo Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=19823518&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL940007(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Akzo Nv filed Critical Akzo Nv
Publication of NL940007I1 publication Critical patent/NL940007I1/nl
Publication of NL940007I2 publication Critical patent/NL940007I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/75—Amino or imino radicals, acylated by carboxylic or carbonic acids, or by sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
NL940007C 1975-04-05 1994-04-21 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwi jze ter bereiding van de toe te passen benz(aryl)azepinederivaten. NL940007I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Publications (2)

Publication Number Publication Date
NL940007I1 true NL940007I1 (nl) 1994-06-01
NL940007I2 NL940007I2 (nl) 1994-10-17

Family

ID=19823518

Family Applications (2)

Application Number Title Priority Date Filing Date
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
NL940007C NL940007I2 (nl) 1975-04-05 1994-04-21 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwi jze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NLAANVRAGE7504075,A NL189199C (nl) 1975-04-05 1975-04-05 Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.

Country Status (17)

Country Link
US (1) US4062848A (nl)
JP (1) JPS5942678B2 (nl)
BE (1) BE840362A (nl)
CA (1) CA1076571A (nl)
CH (1) CH622261A5 (nl)
DE (1) DE2614406A1 (nl)
DK (1) DK142498B (nl)
ES (2) ES446634A1 (nl)
FI (1) FI62087C (nl)
FR (1) FR2305986A1 (nl)
GB (1) GB1543171A (nl)
HU (1) HU179401B (nl)
IE (1) IE42969B1 (nl)
LU (1) LU74680A1 (nl)
NL (2) NL189199C (nl)
SE (1) SE422941B (nl)
ZA (1) ZA761756B (nl)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPS6336682A (ja) * 1986-07-31 1988-02-17 Matsushita Electric Ind Co Ltd カセツト方式文字放送受信機
JPS63177670A (ja) * 1987-01-31 1988-07-21 Fujitsu General Ltd 文字放送受信装置
JPS63215179A (ja) * 1987-03-03 1988-09-07 Fujitsu General Ltd 受信装置
JPH055746Y2 (nl) * 1988-04-27 1993-02-15
NO175781C (no) * 1989-10-05 1994-12-07 Sankyo Co Analogifremgangsmåte for fremstilling av terapeutisk aktive tetracykliske forbindelser
EP0539164A1 (en) * 1991-10-23 1993-04-28 Sankyo Company Limited Nitrogen-containing tetracyclic compounds having anti-allergic and anti-asthmatic activities, their preparation and use
IL121076A (en) * 1996-06-19 2000-10-31 Akzo Nobel Nv Pharmaceutical combinations comprising mirtazapine and one or more selective serotonin reuptake inhibitors
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
AU777105B2 (en) 1999-04-19 2004-09-30 Teva Pharmaceutical Industries Ltd. Novel synthesis of piperazine ring
US6545149B2 (en) 1999-04-19 2003-04-08 Teva Pharmaceutical Industries Ltd. Synthesis and crystallization of piperazine ring-containing compounds
EP1178805A4 (en) * 1999-04-19 2004-11-24 Teva Pharma NOVEL SYNTHESIS AND CRYSTALLIZATION OF PIPERAZINE-CONTAINING COMPOUNDS
TR200103028T2 (tr) * 1999-04-19 2002-01-21 Teva Pharmaceutical Industries Ltd. Piperazin halka içeren bileşiklerin yeni sentezi ve kristalleştirilmesi
US6281207B1 (en) * 1999-09-15 2001-08-28 Reed Richter Treatment of movement disorders by administration of mirtazapine
AU6476300A (en) 1999-09-30 2001-05-10 Sumika Fine Chemicals Co., Ltd. Process for the preparation of a piperazine derivative
AU6019900A (en) * 1999-11-24 2001-06-04 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine crystals and process for producing the same
WO2001042239A1 (fr) 1999-12-13 2001-06-14 Sumika Fine Chemicals Co., Ltd. Procede de preparation d'un compose pyridinemethanol
CA2396066A1 (en) * 2000-01-19 2001-07-26 Akzo Nobel N.V. Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
DE60117122T2 (de) 2000-02-11 2006-07-27 Akzo Nobel N.V. Verwendung von mirtazapin zur behandlung von schlafstörungen
IN190478B (nl) * 2000-11-07 2003-08-02 Sun Pharmaceutical Ind Ltd
US6660730B2 (en) * 2000-11-27 2003-12-09 Sumika Fine Chemicals Co., Ltd. Anhydrous mirtazapine and process for preparing the same
US6399310B1 (en) 2001-02-12 2002-06-04 Akzo Nobel N.V. Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
US20030105082A1 (en) * 2001-12-03 2003-06-05 Murphy Greer Marechal Methods for improving the therapeutic response of humans having major depression and carrying the gene for apolipoprotein E4
ES2296893T3 (es) * 2001-02-12 2008-05-01 N.V. Organon Uso de mirtazapina para el tratamiento de la depresion severa en un paciente humano y portador del gen de la apolipoproteina e4.
WO2002070513A1 (en) * 2001-03-01 2002-09-12 Teva Pharmaceutical Industries Ltd. Methods for the preparation of mirtazapine intermediates
US7355042B2 (en) * 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
CZ296992B6 (cs) * 2002-10-03 2006-08-16 Zentiva, A.S. Príprava a izolace 2-substituovaných-3-pyridylkarboxylových kyselin, jejich karboxylových solí a produktu redukce
US20040192754A1 (en) * 2003-03-24 2004-09-30 Shapira Nathan Andrew Methods for treating idiopathic hyperhidrosis and associated conditions
UA83666C2 (ru) * 2003-07-10 2008-08-11 Н.В. Органон Способ получения энантиомерно чистого миртазапина
US7838029B1 (en) * 2003-07-31 2010-11-23 Watson Laboratories, Inc. Mirtazapine solid dosage forms
TW200538100A (en) * 2004-04-21 2005-12-01 Akzo Nobel Nv Mirtazapine salts
CA2565996A1 (en) * 2004-05-11 2005-11-17 Pfizer Products Inc. Combination of atypical antipsychotics and 5-ht1b receptor antagonists
JP2008509925A (ja) * 2004-08-13 2008-04-03 オメロス コーポレイション 新規のセロトニンレセプターリガンドおよびそれらの使用
US20060039866A1 (en) * 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
JP4848704B2 (ja) * 2004-08-24 2011-12-28 住友化学株式会社 ２−（４−メチル−２−フェニルピペラジン−１−イル）−３−シアノピリジンの製造方法
WO2006022182A1 (ja) * 2004-08-24 2006-03-02 Sumitomo Chemical Company, Limited ２－（４－メチル－２－フェニルピペラジン－１－イル）－３－シアノピリジンの製造方法
TW200631584A (en) * 2004-11-15 2006-09-16 Akzo Nobel Nv A medicament related to mirtazapine for the treatment of hot flush
WO2006055854A2 (en) * 2004-11-17 2006-05-26 Cypress Bioscience, Inc. Methods for reducing the side effects associated with mirtazapine treatment
US20090306046A1 (en) * 2005-06-27 2009-12-10 N.V. Organon Method of treatment of hormone depletion induced vasomotor symptoms
CA2614289A1 (en) 2005-07-08 2007-01-18 Braincells, Inc. Methods for identifying agents and conditions that modulate neurogenesis
CN1939918B (zh) * 2005-09-30 2010-09-01 北京德众万全医药科技有限公司 一种米氮平的制备方法
WO2007047978A2 (en) 2005-10-21 2007-04-26 Braincells, Inc. Modulation of neurogenesis by pde inhibition
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
KR20080065704A (ko) 2005-11-09 2008-07-14 콤비네이토릭스, 인코포레이티드 의학적 이상의 치료 방법들, 조성물들, 및 키트들
CN101304988A (zh) * 2005-11-14 2008-11-12 住友化学株式会社 制备2-(4-甲基-2-苯基哌嗪-1-基)吡啶-3-甲醇的方法
EP1792618A1 (en) 2005-11-30 2007-06-06 Rainer Freynhagen R-mirtazapine for the treatment of pain
JP2009539760A (ja) * 2006-03-06 2009-11-19 ナームローゼ・フエンノートチヤツプ・オルガノン ホルモン枯渇誘発血管運動症状のホルモン療法からの離脱の改良法
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
CA2651813A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
US7858611B2 (en) * 2006-05-09 2010-12-28 Braincells Inc. Neurogenesis by modulating angiotensin
US7678808B2 (en) 2006-05-09 2010-03-16 Braincells, Inc. 5 HT receptor mediated neurogenesis
US20070270413A1 (en) * 2006-05-22 2007-11-22 N.V. Organon Mirtazapine for the treatment of neuropathic pain
TW200815370A (en) * 2006-06-16 2008-04-01 Organon Nv Stereoselective synthesis of (S)-1-methyl-3-phenylpiperazine
EP2068872A1 (en) * 2006-09-08 2009-06-17 Braincells, Inc. Combinations containing a 4-acylaminopyridine derivative
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008083204A2 (en) * 2006-12-28 2008-07-10 Braincells, Inc. Modulation of neurogenesis by melatoninergic ligands
WO2008086483A2 (en) * 2007-01-11 2008-07-17 Braincells, Inc. Modulation of neurogenesis with use of modafinil
JP5192707B2 (ja) * 2007-03-22 2013-05-08 住友化学株式会社 ミルタザピンの製造方法
US20080255348A1 (en) * 2007-04-11 2008-10-16 N.V. Organon Method for the preparation of an enantiomer of a tetracyclic benzazepine
CA2682932A1 (en) * 2007-04-11 2008-10-23 N.V. Organon A method for the preparation of an enantiomerically pure benzazepine
EP2146993B1 (en) 2007-04-11 2015-08-05 Merck Sharp & Dohme B.V. A method for the preparation of mirtazapine
US7994314B2 (en) * 2007-04-11 2011-08-09 N.V. Organon Method for the preparation of an enantiomerically pure benzazepine
WO2008157094A1 (en) * 2007-06-13 2008-12-24 Cypress Bioscience, Inc. Improving the tolerability of mirtazapine and a second active by using them in combination
JP2009018992A (ja) * 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
EP2291181B9 (en) 2008-04-18 2013-09-11 University College Dublin National University Of Ireland, Dublin Captodiamine for the treatment of depression symptoms
WO2009128058A1 (en) 2008-04-18 2009-10-22 UNIVERSITY COLLEGE DUBLIN, NATIONAL UNIVERSITY OF IRELAND, DUBLIN et al Psycho-pharmaceuticals
JP2011526881A (ja) * 2008-06-25 2011-10-20 ファイザー・インク ジアリール化合物およびそれらの使用
WO2010046851A1 (en) 2008-10-22 2010-04-29 Watson Pharma Private Limited Process for the preparation of 1- ( 3-hydroxymethylpyrid-2 -yl ) -2 -phenyl-4-methylpiperazine and mirtazapine
WO2010099217A1 (en) 2009-02-25 2010-09-02 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
CN102432594B (zh) * 2011-11-28 2013-09-11 山东鲁药制药有限公司 一种药物中间体1-（3-羟甲基吡啶-2-基）-2-苯基-4-甲基哌嗪的制备方法
CN103509020A (zh) * 2013-10-21 2014-01-15 山东鲁药制药有限公司 一种米氮平的合成方法
CN104356133A (zh) * 2014-11-25 2015-02-18 南京工业大学 一种制备抗抑郁药物米氮平的方法
JP6433809B2 (ja) * 2015-02-20 2018-12-05 株式会社トクヤマ １−（３−ヒドロキシメチルピリジル−２−）−２−フェニル−４−メチルピペラジンの製造方法
KR102540021B1 (ko) 2020-12-02 2023-06-07 (주)유케이케미팜 대량 생산에 적합한 미르타자핀의 제조방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL129434C (nl) * 1966-03-12
NL7202963A (nl) * 1972-03-07 1973-09-11
US3959470A (en) * 1972-11-28 1976-05-25 Mikhail Davidovich Mashkovsky Psychotropic medicinal preparation

Also Published As

Publication number Publication date
DE2614406C2 (nl) 1992-02-20
JPS5942678B2 (ja) 1984-10-16
FI62087C (fi) 1982-11-10
DE2614406A1 (de) 1976-10-14
ZA761756B (en) 1977-03-30
JPS51122099A (en) 1976-10-25
NL189199C (nl) 1993-02-01
CA1076571A (en) 1980-04-29
NL189199B (nl) 1992-09-01
IE42969B1 (en) 1980-11-19
SE422941B (sv) 1982-04-05
FI760884A (nl) 1976-10-06
FR2305986A1 (fr) 1976-10-29
HU179401B (en) 1982-10-28
SE7603931L (sv) 1976-10-06
DK142498B (da) 1980-11-10
FR2305986B1 (nl) 1980-06-13
ES459348A1 (es) 1978-03-16
CH622261A5 (nl) 1981-03-31
AU1236176A (en) 1977-09-29
ES446634A1 (es) 1977-11-01
BE840362A (fr) 1976-10-04
US4062848A (en) 1977-12-13
LU74680A1 (nl) 1976-11-11
NL940007I2 (nl) 1994-10-17
NL7504075A (nl) 1976-10-07
DK142676A (nl) 1976-10-06
DK142498C (nl) 1981-07-06
FI62087B (fi) 1982-07-30
IE42969L (en) 1976-10-05
GB1543171A (en) 1979-03-28

Similar Documents

Publication Publication Date Title
NL940007I1 (nl) Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten de verkregen gevormde farmaceutische preparaten alsmede werkwijzeter bereiding van de toe te passen benz(aryl)azep inederivaten
NL190721C (nl) Werkwijze voor het bereiden van 3-hydroxy-cephem derivaten.
NL7609292A (nl) Werkwijze voor het bereiden van heteroarylben- zoxepine-azijnzuren, voorlopers en derivaten daarvan.
NL7606908A (nl) Benzofurancarbonzuurderivaten en farmaceutisch preparaat alsmede werkwijze voor het bereiden daarvan.
NL7609414A (nl) Werkwijze ter bereiding van farmaceutische preparaten en werkwijze ter bereiding van 1-sulfonylbenzimidazoolderivaten.
NL186009C (nl) Werkwijze voor het bereiden van op de 3-plaats gesubstitueerde 7-aminocefem derivaten.
NL7604129A (nl) Werkwijze voor de bereiding van hydroxycarbon- zuren en derivaten ervan.
NL7602634A (nl) Verbeterde werkwijze voor het bereiden van amoxicilline-trihydraat.
NL7610586A (nl) Werkwijze voor het bereiden van polyesteramiden.
NL180852C (nl) Werkwijze voor de bereiding van aminoacylase-dragercomplexen, alsmede werkwijze voor het bereiden van l-aminozuren onder toepassing van deze aminoacylase-dragercomplexen.
NL7614445A (nl) Werkwijze voor het bereiden van cyclische benzoxazinen en benzothiazinen.
NL7606824A (nl) Werkwijze voor het bereiden van een oraal preparaat.
NL7609286A (nl) Werkwijze voor het bereiden van 3-fenylspiro(iso- benzofuran-1.4'-piperidine)-sulfenamiden en derivaten daarvan.
NL7609832A (nl) Werkwijze voor het bereiden van een voor intra- veneuze toediening geschikte gammaglobuline- oplossing.
NL186696C (nl) Werkwijze voor het bereiden van 4-oxohexahydro-pyrazinoisochinolinederivaten.
NL7608164A (nl) Werkwijze voor het bereiden van cefem- en penamverbindingen, alsmede werkwijze ter bereiding van farmaceutische preparaten.
NL7612320A (nl) Werkwijze voor het bereiden van thiaprostaan- zuurderivaten.
NL7609240A (nl) Werkwijze voor het bereiden van derivaten van 7-amino-3-cefem-4-carbonzuur, de daarvan afge- leide zouten, werkwijze voor het bereiden van farmacologische preparaten, alsmede de gevorm- de preparaten.
NL7707062A (nl) Werkwijze voor het bereiden van bicyclische en tricyclische carbostyrilderivaten alsmede van farmaceutische preparaten.
HU173879B (hu) Sposob poluchenija proizvodnykh tetrazolil- i tetrazolilalkil-imidazola i benzimidazola i farmacepticheskikh preparatov, soderzhahhikh ehti soedinenija v kachestve aktivnykh vehhestv
NL7609662A (nl) Werkwijze voor het bereiden van op de 14-plaats gesubstitueerde vincaan-derivaten en werkwijze voor de bereiding van een geneesmiddel met vaso-actieve en spasmolytische werking.
NL7609458A (nl) Fenothiazinederivaten alsmede werkwijze voor het bereiden daarvan.
NL7606315A (nl) Werkwijzen voor het bereiden en toepassen van azepinederivaten.
NL7610915A (nl) Oxanilzuurderivaten alsmede werkwijze voor het bereiden daarvan.
AT342761B (de) Verfahren zur herstellung von homopyrimidazol-derivate enthaltenden, stabilen pharmazeutischen praparaten zur oralen verabreichung